Abstract
Prostacyclin is the main arachidonic acid metabolite produced by the arterial walls (2,3,7) and released into circulation (1,4). In man, prostacyclin acts as a powerful vasodilator and anti-platelet agent (13). Resistance vessels are most susceptible for prostacyclin vasodilatory action, while capacitance vessels show little, if any change, even during administration of high doses of prostacyclin (18). The profound anti-platelet effects induced by prostacyclin can be devided into anti-aggregatory and disaggregatory (5,12,13). The former are reflected by a marked inhibition of ADP — or collagen — induced platelet aggregation, the latter by dispersion of both circulating platelet aggregates and platelet thrombi formed on the collagen surface.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R.J. Gryglewski, Prostacyclin as a circulating hormone. Biochem. Pharmacol. 28: 3161 (1979).
R.J. Gryglewski, Prostaglandins, platelets, and atherosclerosis. CRC series in Biochemistry 7: 291 (1980).
R.J. Gryglewski, S. Bunting, S. Moncada, R.J. Flower, J.R. Vane, Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12: 685 (1976).
R.J. Gryglewski, R. Korbut, A. Ocetkiewicz, Generation of prostacyclin by lungs in vivo and its release into arterial circulation. Nature 273: 765 (1978).
R.J. Gryglewski, A. Szczeklik, R. Nizankowski, Antiplatelet action of intravenous prostacyclin in man. Thrombos. Res. 13:152 (1978).
R.J. Gryglewski, A. Szczeklik, H. Zygulska-Mach, E. Kostaka-Trabka, Prostacyclin and vascular disease. Symposium A. Einstein Coll. of Med., 28–30 October 1980. Raven Press, New York — in press.
S. Moncada, R.J. Gryglewski, S. Bunting, J.R. Vane, A lipid peroxide inhibits the enzyme that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelets from aggregation. Prostaglandins 12: 715 (1976).
A. Szczeklik, Prostacyclin and atherosclerosis. Triangle 19: 61 (1980).
A. Szczeklik, Cardiovascular actions of prostacyclin in man. International conference on prostaglandins, New york, April 1980, in press.
A. Szczeklik, R.J. Gryglewski, Treatment of vascular disease with prostacyclin. In Clinical pharmacology of prostacyclin, ed. by P. Lewis and J. O’Grady, in press.
A. Szczeklik, R.J. Gryglewski, Prostaglandins as therapeutical agents in cardiovascular disease. Proceedings of the meeting “Prostaglandins and the cardiovascular system”, Wilrijk (Belgium) 1–3 December 1980, in press (Raven Press).
A. Szczeklik, R.J. Gryglewski, E. Nizankowska, R. Nizankowski, J. Musial, Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins 16: 651 (1978).
A. Szczeklik, R.J. Gryglewski, R. Nizankowski, J. Musial, R. Pieton, J. Murk, Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol. Res. Commun. 10: 545 (1978).
A. Szczeklik, R.J. Gryglewski, R. Nizankowski, S. Skawinski, P. Gluszko, Prostacyclin therapy of peripheral vascular disease. Thrombos. Res. 19: 191 (1980).
A. Szczeklik, R. Nizankowski, S. Skawinski, J. Szczeklik, P. Gluszko, R.J. Gryglewski, Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1: 1111 (1979).
A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Gluszco, Prostacyclin for unstable angina. N. Engl. J. Med. 303: 881 (1980).
A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Gluszko, Prostacyclin for acute coronary insufficiency. Artery — in press.
J. Szczeklik, A. Szczeklik, R. Nizankowski, Haemodynamic changes induced by prostacyclin in man. Br. Heart J. 44: 254 (1980).
J. Szczeklik, A. Szczeklik, R. Nizankowski, Prostacyclin for pulmonary hypertension. Lancet 2: 1076 (1980).
W.D. Watkins, M.P. Peterson, R.K. Brone, D.C. Shannon, L. Levine, Prostacyclin and prostaglandin E. for severe pulmonary artery hypertension. Lancet 1: 1083 (1980).
H. Zygulska-Mach, E. Kostka-Trabka, A. Niton, R.J. Gryglewski, Prostacyclin in central retinal vein occlusion. Lancet 2: 1075 (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
Gryglewski, R.J., Szczeklik, A. (1984). Prostacyclin in the Treatment of Atherosclerosis Obliterans and Other Vascular Diseases. In: Strano, A. (eds) Thrombosis and Cardiovascular Disease. Advances in Experimental Medicine and Biology, vol 164. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8616-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8616-2_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8618-6
Online ISBN: 978-1-4684-8616-2
eBook Packages: Springer Book Archive